• 1. Department of Infectious Diseases, The Second People's Hospital of Lanzhou City, Lanzhou 730046, P. R. China;
  • 2. Department of Health Policy and Management, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
LI Sheng1, Email: 1178708407@qq.com
Export PDF Favorites Scan Get Citation

Objective To systematically review the recommendations for antiretroviral therapy in the AIDS guidelines, and summarize the sources of evidence supporting the recommendations, the quality of the evidence and the strength of the recommendations, and the consistency of the recommendations. Methods We systematically searched for articles published before Dec 2024 in PubMed, Web of Science, Embase, CNKI, Wanfang, VIP, Chinese Biomedical Literature Database, World Health Organization, NICE, GIN, Medsci, Medlive and Chinese Medical Association HIV guidelines in other databases, integrating recommendations. Quality and reporting practices were evaluated using AGREE Ⅱ and RIGHT tools respectively. Results The average score of AGREE Ⅱ was 62 points, the overall reporting rate was 69.68%, and the quality of methodology and reporting specifications were low. Analysis of the recommendation results showed that a total of 57 recommendations for ART therapy were extracted from 18 guidelines, mainly recommending 2 NRTIs combined with third-category drugs. NRTI drugs are mainly based on TDF+FTC (3TC), TAF+FTC, and ABC+3TC. The third category of drugs recommended by various guidelines with relatively high frequency includes INSTI(DTG, BIC, RAL),NNRTI(EFV) and PIs(DRV/r). The third category of drugs recommended with relatively high frequency in alternative therapies includes INSTI(DTG, RAL),NNRTI(EFV,RPV) and PI(DRV/c). Conclusion The methodological quality and reporting specifications of the HIV clinical practice guidelines need to be improved. The evidence grading of the guidelines is not standardized, there are differences in the combination of drugs recommended by each guideline, the strength of recommendations and the quality of the evidence are inconsistent, and there are obvious differences in the sources of evidence to support the opinions. In the future, it is necessary to combine high-quality clinical trials or randomized controlled trials, adopt systematic and rigorous evidence level and recommendation grading standards when necessary, and provide high-quality evidence sources to formulate complete guidelines. Specific conditions such as the patient's biological indicators should also be fully considered to clarify which virological and biological indicators ART therapy is suitable for, so as to provide precise treatment.

Copyright ? the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved